<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209234</url>
  </required_header>
  <id_info>
    <org_study_id>2010-7710</org_study_id>
    <nct_id>NCT01209234</nct_id>
  </id_info>
  <brief_title>Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial will compare strategies to reduce the risk of&#xD;
      methicillin-resistant Staphylococcus aureus (MRSA) infection and re-hospitalization in MRSA&#xD;
      carriers. This trial will provide critical answers about the role of decolonization versus&#xD;
      standard-of-care education in preventing MRSA infections in the large group of high risk&#xD;
      MRSA-positive patients being discharged from hospitals. Findings could potentially impact&#xD;
      best practice for the 1.8 million MRSA carriers who are discharged from US hospitals each&#xD;
      year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled trial will compare strategies to reduce the risk of&#xD;
      methicillin-resistant Staphylococcus aureus (MRSA) infection and re-hospitalization in MRSA&#xD;
      carriers. This trial will provide critical answers about the role of decolonization versus&#xD;
      standard-of-care education in preventing MRSA infections in the large group of high risk&#xD;
      MRSA+ patients being discharged from hospitals. Findings could potentially impact best&#xD;
      practice for the 1.8 million MRSA carriers who are discharged from US hospitals each year.&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
      Methicillin-resistant Staphylococcus aureus (MRSA) is arguably the most important single&#xD;
      pathogen in healthcare-associated infection when accounting for virulence, prevalence,&#xD;
      diversity of disease spectrum, and propensity for widespread transmission. MRSA infection&#xD;
      causes or complicates 300,000 hospitalizations each year [Klein, Smith, Laxminarayan], a&#xD;
      number which has doubled in the past five years. An additional 1.5 million hospitalized&#xD;
      patients either acquire or already harbor the pathogen without current infection. Altogether,&#xD;
      these 1.8 million MRSA inpatient carriers experience a high amount of MRSA invasive disease&#xD;
      in the year following discharge. Due to increased delivery of complex medical care at home or&#xD;
      other post-hospital settings, more and more patients experience serious healthcare-associated&#xD;
      morbidity after hospital discharge.[Huang, Platt; Huang, Hinrichsen, Stulgis et al.] In fact,&#xD;
      over 80% of patients admitted for MRSA infection have had prior healthcare exposures and are&#xD;
      at high risk for repeated MRSA infection.[Huang, Platt; Huang, Hinrichsen, Stulgis et al.;&#xD;
      Klevens, Morrison, Nadle, et al.]&#xD;
&#xD;
      Project CLEAR compares two strategies to reduce infection and re-hospitalization due to MRSA&#xD;
      among patients being discharged from hospitals. Our trial will compare a long-term regimen&#xD;
      aimed at eradicating MRSA body reservoirs with patient education on general hygiene and self&#xD;
      care, which is the current standard of care. Our specific aims are:&#xD;
&#xD;
        -  To conduct a randomized controlled trial of serial decolonization versus&#xD;
           standard-of-care patient education among MRSA carriers upon hospital discharge to reduce&#xD;
           post-discharge MRSA infection and re-hospitalization for one year&#xD;
&#xD;
        -  To identify predictors of a) infection or re-hospitalization due to MRSA, and b)&#xD;
           successful MRSA decolonization, including patient demographics, comorbidities, medical&#xD;
           devices, risk behaviors, socioeconomic status, and colonizing MRSA genotype&#xD;
&#xD;
        -  To estimate medical and non-medical costs of MRSA infection among MRSA carriers and&#xD;
           evaluate the potential for cost savings associated with decolonization&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to MRSA Infection</measure>
    <time_frame>1 year</time_frame>
    <description>Time in days to MRSA inpatient or outpatient infection (analyzed with the use of unadjusted Cox proportional-hazard models to identify time to infection; the results we are reporting are number of participants who had an infection event at one year post discharge)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to All-cause Infection (Steering Committee Modified Oct 2011)</measure>
    <time_frame>1 year</time_frame>
    <description>Time in days to all-cause infection (analyzed with the use of unadjusted Cox proportional-hazard models to identify time to infection; the results we are reporting are number of participants who had an infection event at one year)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of MRSA Infections</measure>
    <time_frame>1 year</time_frame>
    <description>Event count of outpatient and inpatient MRSA infections occurring after enrollment</description>
  </other_outcome>
  <other_outcome>
    <measure>Rehospitalization Due to MRSA Infection</measure>
    <time_frame>1 year</time_frame>
    <description>Time in days to rehospitalization due to MRSA infection</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost and Cost Savings Associated With Post-discharge MRSA Decolonization</measure>
    <time_frame>1 year</time_frame>
    <description>Medical and non-medical costs of MRSA infection within the 1 year follow up period</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of All-cause Infections (Steering Committee Modified Oct 2011)</measure>
    <time_frame>1 year</time_frame>
    <description>Event count of all-cause infections occurring after enrollment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2140</enrollment>
  <condition>Methicillin-resistant Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>MRSA Decolonization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Education Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard-of-Care Education</intervention_name>
    <description>Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.</description>
    <arm_group_label>Education Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRSA Decolonization</intervention_name>
    <description>Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.</description>
    <arm_group_label>MRSA Decolonization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) At least 18 years old&#xD;
&#xD;
          -  2) Have had a positive culture (a type of test) for MRSA during recent hospital&#xD;
             admission or within the 30 days prior to admission or following discharge&#xD;
&#xD;
          -  3) Able to give consent or have a primary caregiver provide consent&#xD;
&#xD;
          -  4) Able to bathe or shower or have this consistently performed by a willing caregiver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Known allergies to chlorhexidine or mupirocin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan S Huang, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irivne - School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covington Care Center</name>
      <address>
        <city>Aliso Viejo</city>
        <state>California</state>
        <zip>92656</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Anaheim Extended Care</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downey Regional Medical Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fountain Valley Regional Hospital &amp; Medical Center</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange Coast Memorial Medical Center</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapman Care Center</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Haven HealthCare Center</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regents Point at Windcrest</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saddleback Memorial Medical Center - Laguna Hills</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Villa Elena Health Care Center</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saddleback Memorial Medical Center - San Clemente</name>
      <address>
        <city>San Clemente</city>
        <state>California</state>
        <zip>92673</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Company of Mary - San Pedro</name>
      <address>
        <city>San Pedro</city>
        <state>California</state>
        <zip>90732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Country Villa Plaza</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royale Healthcare</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Little Company of Mary Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura County Medical Center</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007 Dec;13(12):1840-6. doi: 10.3201/eid1312.070629.</citation>
    <PMID>18258033</PMID>
  </reference>
  <reference>
    <citation>Huang SS, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis. 2003 Feb 1;36(3):281-5. Epub 2003 Jan 17.</citation>
    <PMID>12539068</PMID>
  </reference>
  <reference>
    <citation>Huang SS, Hinrichsen VH, Stulgis L, Miroshnik I, Datta R, Watson K, Platt R. Methicillin-resistant Staphylococcus aureus Infection in the Year Following Detection of Carriage (oral presentation). Society of Healthcare Epidemiology of America Annual Meeting (Chicago, IL), March 18-21, 2006.</citation>
  </reference>
  <reference>
    <citation>Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007 Oct 17;298(15):1763-71.</citation>
    <PMID>17940231</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <results_first_submitted>August 12, 2019</results_first_submitted>
  <results_first_submitted_qc>August 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2020</results_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Susan Huang</investigator_full_name>
    <investigator_title>Director of Epidemiology and Infection Prevention</investigator_title>
  </responsible_party>
  <keyword>Methicillin-resistant Staphylococcus aureus</keyword>
  <keyword>MRSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 7, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT01209234/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT01209234/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred between January 10, 2011 and January 2, 2014, during inpatient admissions in 17 hospitals and 7 nursing homes in Southern California.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MRSA Decolonization</title>
          <description>Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.&#xD;
MRSA Decolonization: Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.</description>
        </group>
        <group group_id="P2">
          <title>Education Arm</title>
          <description>Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.&#xD;
Standard-of-Care Education: Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1070"/>
                <participants group_id="P2" count="1070"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1058"/>
                <participants group_id="P2" count="1063"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MRSA Decolonization</title>
          <description>Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.&#xD;
MRSA Decolonization: Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.</description>
        </group>
        <group group_id="B2">
          <title>Education Arm</title>
          <description>Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.&#xD;
Standard-of-Care Education: Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1058"/>
            <count group_id="B2" value="1063"/>
            <count group_id="B3" value="2121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="17"/>
                    <measurement group_id="B2" value="56" spread="17"/>
                    <measurement group_id="B3" value="56" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                    <measurement group_id="B2" value="480"/>
                    <measurement group_id="B3" value="973"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="565"/>
                    <measurement group_id="B2" value="583"/>
                    <measurement group_id="B3" value="1148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="840"/>
                    <measurement group_id="B2" value="844"/>
                    <measurement group_id="B3" value="1684"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="256"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown/Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1058"/>
                    <measurement group_id="B2" value="1063"/>
                    <measurement group_id="B3" value="2121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to MRSA Infection</title>
        <description>Time in days to MRSA inpatient or outpatient infection (analyzed with the use of unadjusted Cox proportional-hazard models to identify time to infection; the results we are reporting are number of participants who had an infection event at one year post discharge)</description>
        <time_frame>1 year</time_frame>
        <population>Outcomes were analyzed according to the as-treated adherence strata (fully adherent, partially adherent, and nonadherent participant-time)</population>
        <group_list>
          <group group_id="O1">
            <title>MRSA Decolonization</title>
            <description>Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.&#xD;
MRSA Decolonization: Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.</description>
          </group>
          <group group_id="O2">
            <title>Education Arm</title>
            <description>Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.&#xD;
Standard-of-Care Education: Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to MRSA Infection</title>
          <description>Time in days to MRSA inpatient or outpatient infection (analyzed with the use of unadjusted Cox proportional-hazard models to identify time to infection; the results we are reporting are number of participants who had an infection event at one year post discharge)</description>
          <population>Outcomes were analyzed according to the as-treated adherence strata (fully adherent, partially adherent, and nonadherent participant-time)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1058"/>
                <count group_id="O2" value="1063"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MRSA Infection defined by CDC Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRSA Infection defined by Clinical Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>This is the estimated standard error of the log hazard ratio</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to All-cause Infection (Steering Committee Modified Oct 2011)</title>
        <description>Time in days to all-cause infection (analyzed with the use of unadjusted Cox proportional-hazard models to identify time to infection; the results we are reporting are number of participants who had an infection event at one year)</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRSA Decolonization</title>
            <description>Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.&#xD;
MRSA Decolonization: Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.</description>
          </group>
          <group group_id="O2">
            <title>Education Arm</title>
            <description>Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.&#xD;
Standard-of-Care Education: Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to All-cause Infection (Steering Committee Modified Oct 2011)</title>
          <description>Time in days to all-cause infection (analyzed with the use of unadjusted Cox proportional-hazard models to identify time to infection; the results we are reporting are number of participants who had an infection event at one year)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1058"/>
                <count group_id="O2" value="1063"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-Cause Infection defined by CDC Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-Cause Infection defined by Clinical Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.061</p_value>
            <p_value_desc>Not adjusted for multiple comparisons</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.009</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>CDC-defined all-cause infection secondary outcome This is the estimated standard error of the log hazard ratio</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>Not adjusted for multiple comparisons</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.008</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Clinical criteria for all-cause infection This is the estimated standard error of the log hazard ratio</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of MRSA Infections</title>
        <description>Event count of outpatient and inpatient MRSA infections occurring after enrollment</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rehospitalization Due to MRSA Infection</title>
        <description>Time in days to rehospitalization due to MRSA infection</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cost and Cost Savings Associated With Post-discharge MRSA Decolonization</title>
        <description>Medical and non-medical costs of MRSA infection within the 1 year follow up period</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of All-cause Infections (Steering Committee Modified Oct 2011)</title>
        <description>Event count of all-cause infections occurring after enrollment</description>
        <time_frame>1 year</time_frame>
        <posting_date>04/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were actively assessed from January 2011-January 2015. Participants were recruited from January 2011-January 2014 and were followed for 1 year. Evaluation of the full text medical record reviews for adverse events occurred for several years after recruitment ended in 2014.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MRSA Decolonization</title>
          <description>Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.&#xD;
MRSA Decolonization: Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.</description>
        </group>
        <group group_id="E2">
          <title>Education Arm</title>
          <description>Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.&#xD;
Standard-of-Care Education: Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1058"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1058"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="1058"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Mupirocin (2%)</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Nasal Mupirocin (2%)</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Nasal Mupirocin (2%)</sub_title>
                <description>Numb throat, tast change</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Nasal Mupirocin (2%)</sub_title>
                <description>Runny, itchy nose</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Nasal Mupirocin (2%)</sub_title>
                <description>Runny nose</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Nasal Mupirocin (2%)</sub_title>
                <description>Loss of smell and taste</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Mouthwash (0.12%)</sub_title>
                <description>Tongue discoloration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Mouthwash (0.12%)</sub_title>
                <description>Tingling tongue</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Mouthwash (0.12%)</sub_title>
                <description>Tingling of mouth</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Mouthwash (0.12%)</sub_title>
                <description>Teeth staining</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Mouthwash (0.12%)</sub_title>
                <description>Dry mouth</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Mouthwash (0.12%)</sub_title>
                <description>Oral irritation</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Mupirocin (2%)</sub_title>
                <description>Congestion</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Itchy, dry hands</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Itchy body</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Itchy face and neck</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Itchy, dry scalp</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Dry skin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Dry, flaky hands and feet</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Burning sensation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Rash: trunk</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Rash: body</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Rash: face and neck</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Rash: chest</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Rash: legs</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Rash: scrotal</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Rash: neck, limbs</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Rash and dryness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
              <event>
                <sub_title>Chlorhexidine Bodywash (4%)</sub_title>
                <description>Rash: leg</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1058"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1063"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Huang, Principal Investigator &amp; Medical Director of Epidemiology and Infection Prevention</name_or_title>
      <organization>University of California, Irvine</organization>
      <phone>949-824-5073</phone>
      <email>sshuang@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

